Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future outlook: changing perspectives on best practice.

Daniel J Rader1

  • 1University of Pennsylvania School of Medicine, Philadelphia, USA.

The American Journal of Managed Care
|February 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

The New England journal of medicine·2017
Same author

Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms.

Nature genetics·2017
Same author

Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress.

Cell reports·2017
Same author

Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.

Circulation research·2017
Same author

Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity.

The Journal of clinical investigation·2017
Same author

Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis.

The Journal of biological chemistry·2017
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

New guidelines recommend aggressive low-density lipoprotein (LDL) cholesterol lowering. Ezetimibe offers an effective alternative therapy, reducing LDL by 18% when used alone or with statins.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • National Cholesterol Education Program guidelines advocate for more aggressive low-density lipoprotein (LDL) cholesterol reduction.
  • While statins are effective, alternative therapies are necessary for patients intolerant to or ineligible for statin treatment.
  • Existing alternative therapies have limitations in efficacy, tolerability, and patient compliance.

Purpose of the Study:

  • To evaluate ezetimibe as a selective inhibitor of intestinal cholesterol absorption.
  • To assess the efficacy of ezetimibe as a monotherapy or in combination with statins for lowering LDL cholesterol levels.

Main Methods:

  • Review of existing literature on cholesterol-lowering therapies.
  • Analysis of ezetimibe's mechanism of action as a selective cholesterol absorption inhibitor.

Related Experiment Videos

  • Evaluation of clinical data on ezetimibe's efficacy in reducing LDL cholesterol levels.

    • Main Results:

    • Ezetimibe selectively inhibits intestinal cholesterol absorption.
    • Once-daily ezetimibe monotherapy reduced LDL cholesterol by an average of 18%.
    • Combination therapy with statins also demonstrated significant LDL reduction.

    Conclusions:

    • Ezetimibe presents a promising alternative to existing cholesterol-lowering therapies.
    • Its selective mechanism and convenient dosing improve treatment options for patients.
    • Ezetimibe effectively lowers LDL cholesterol, addressing unmet needs in lipid management.